Anti-MEK2 Polyclonal Antibody for WB, IHC-P, IF/ICC, ELISA - P36507

Core Product Specifications and Parameters

Biological Background: MEK2 Function and Localization

• MEK2, also referred to as dual specificity mitogen-activated protein kinase kinase 2 or ERK activator kinase 2, is a member of the MAP kinase kinase family.
• It catalyzes the phosphorylation of both threonine and tyrosine residues within the Thr-Glu-Tyr motif of MAP kinases, leading to activation of ERK1 and ERK2.
• MEK2 contributes to BRAF activation via a KSR1- or KSR2-dependent mechanism, promoting BRAF dimerization and downstream signaling. Related references: PMID:29433126
• Subcellularly, MEK2 is located in the cytoplasm and at the membrane, consistent with its role in relaying signals from cell surface receptors.
• The protein has a molecular weight of approximately 44 kDa and is subject to regulatory modifications including phosphorylation and acetylation.
• Keywords associated with MEK2 include cardiomyopathy, ectodermal dysplasia, and intellectual disability, reflecting links to developmental and disease processes.

Experimental Guidance and Technical Tips

• The immunogen corresponds to an N-terminal peptide (aa 1-100), suggesting reactivity with both unphosphorylated and phosphorylated MEK2. Validate specificity in your physiological context.
• For WB, expect a band near 44 kDa; optimize blocking and antibody concentration to reduce background.
• In IHC-P and IF/ICC, suitable antigen retrieval and permeabilization protocols are critical. Include positive and negative tissue/cell controls.
• This polyclonal antibody is applicable to ELISA; consider pairing with a suitable detection antibody for sandwich assay development.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides a broad portfolio of IVD raw materials, including validated MEK2 antibodies and supporting reagents for MAPK pathway research. Our one-stop sourcing capabilities encompass monoclonal/polyclonal antibody development, bulk production, and customized procurement of rare targets, streamlining your transition from concept to clinic.